ETrade Capital Management’s NovoCure NVCR Stock Holding History

ETrade Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1.08M	Buy	9,716 +10	+0.1%	+$800	0.02%	346
2020 Q2	$575K	Buy	9,706 +432	+5%	+$28.4K	0.01%	505
2020 Q1	$625K	Buy	9,274 +605	+7%	+$47.8K	0.02%	412
2019 Q4	$731K	Sell	8,669 -5,256	-38%	-$424K	0.02%	450
2019 Q3	$1.04M	Sell	13,925 -13,362	-49%	-$1.07M	0.03%	337
2019 Q2	$1.73M	Buy	27,287 +5,957	+28%	+$302K	0.05%	236
2019 Q1	$1.03M	Buy	21,330 +2,965	+16%	+$143K	0.03%	324
2018 Q4	$615K	Buy	18,365 +1,825	+11%	+$66.7K	0.02%	434
2018 Q3	$867K	Buy	16,540 +9,512	+135%	+$379K	0.02%	404
2018 Q2	$220K	Buy	+7,028	New	+$195K	0.01%	737

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ETrade Capital Management's NVCR Position: Q3 2020 in Review

ETrade Capital Management increased its NovoCure (NVCR) stake by 0.1% in Q3 2020, buying an estimated $800 and bringing the position to 9,716 shares worth $1.08M. The position accounts for 0.02% of the portfolio, ranked #346.

ETrade Capital Management first reported a position in NVCR in Q2 2018 and has held it in 10 quarters since. The position peaked at $1.73M in Q2 2019. 282 funds tracked by Wall St. Rank hold NVCR as of Q3 2020.

ETrade Capital Management held 9,716 shares of NovoCure worth $1.08M as of Q3 2020.
ETrade Capital Management bought 10 NovoCure shares in Q3 2020, an estimated $800.
NovoCure made up 0.02% of ETrade Capital Management's portfolio in Q3 2020, its #346 holding.
ETrade Capital Management first reported a position in NovoCure in Q2 2018 and has held it in 10 quarters since.
ETrade Capital Management's NovoCure position peaked at $1.73M in Q2 2019.
282 funds tracked by Wall St. Rank held NovoCure as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.